Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "Low affinity sodium-glucose cotransporter (SLC5A4) pseudogene" (ENSG00000264503) is a pseudogene in humans, meaning it resembles the functional SLC5A4 gene but does not produce an active protein. The functional SLC5A4 gene encodes the protein SGLT3, a member of the sodium-glucose cotransporter family, which in contrast to other family members (such as SGLT1 or SGLT2), acts primarily as a glucose sensor rather than a transporter. However, as a pseudogene, ENSG00000264503 has no known biological function, does not participate in glucose transport, and is not considered a target for drugs or therapeutic intervention[1][5][7]. Pseudogene status means it cannot perform any molecular function nor serve as a direct drug target. No current evidence connects this pseudogene to disease processes, biomarkers, or therapeutic safety concerns. This entry should not be used as a target for drug discovery, clinical, or molecular biology purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Low affinity sodium-glucose cotransporter (SLC5A4) pseudogene.